Sanofi’s Insulin Aspart Biosimilar Gets European Nod
As Accord’s Cabazitaxel And Fingolimod Are Endorsed By CHMP
Sanofi has received a positive opinion from the CHMP for its insulin aspart biosimilar rival to NovoRapid. Meanwhile, Accord and Janssen-Cilag have also received positive opinions for generics and hybrid medicines.
